Abstract
No public abstract is available from the verified source records.
Trine Lembrecht Jørgensen, Jesper Hallas, Lotte Holm Land, Jørn Herrstedt
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
No local reference links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies
10.1002/1097-0142(19950715)76:2<333::aid-cncr2820760226>3.0.co;2-i · 1995
Representation of older patients in cancer treatment trials
10.1002/1097-0142(19941001)74:7+<2208::aid-cncr2820741737>3.0.co;2-# · 1994
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups
10.1200/jco.2006.09.2759 · 2007
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials
10.1186/1471-2407-6-34 · 2006
Aging, frailty, and chemotherapy
10.1177/107327480701400102 · 2007
Greater risks of chemotherapy toxicity in elderly patients with cancer
2003
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study
10.1200/jco.20.2.494 · 2002
Impairment in functional status and survival in patients with acute myeloid leukaemia
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1007/s00432-006-0115-7 · 2006
Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service
10.1016/j.critrevonc.2008.07.003 · 2008
Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine
10.1007/s12094-007-0019-2 · 2007
10.1200/jco.2005.02.527
10.1200/jco.2005.02.527 · 2005
Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988
10.1046/j.1532-5415.2003.51471.x · 2003
A practical approach to geriatric assessment in oncology
10.1200/jco.2006.10.2954 · 2007
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)
10.1016/j.critrevonc.2005.06.003 · 2005
Comprehensive geriatric assessment for older patients with cancer
10.1200/jco.2007.10.6559 · 2007
Cancer and comorbidity: redefining chronic diseases
10.1002/(sici)1097-0142(20000201)88:3<653::aid-cncr24>3.0.co;2-1 · 2000
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study
10.1002/(sici)1097-0142(19980601)82:11<2123::aid-cncr6>3.0.co;2-w · 1998
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55years and older
10.1001/jama.285.7.885 · 2001
Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale
10.1016/j.critrevonc.2006.11.001 · 2007
Measurement and impact of comorbidity in older cancer patients
10.1016/s1040-8428(00)00090-1 · 2000
Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study
10.1002/cncr.21354 · 2005
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
10.1002/cncr.23462 · 2008
Association of comorbidity with disability in older women: the Women's Health and Aging Study
10.1016/s0895-4356(98)00124-3 · 1999
Comorbidity and functional status are independent in older cancer patients
10.1200/jco.1998.16.4.1582 · 1998
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome
10.1179/joc.2005.17.6.685 · 2005
Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel
10.1080/02841860600833178 · 2007
Effects of comorbidity on screening and early diagnosis of cancer in elderly people
10.1016/s1470-2045(08)70336-x · 2009
How to measure comorbidity. a critical review of available methods
10.1016/s0895-4356(02)00585-1 · 2003
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
10.1016/0021-9681(87)90171-8 · 1987
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery
10.1016/j.jclinepi.2005.07.015 · 2006
Cumulative illness rating scale
10.1111/j.1532-5415.1968.tb02103.x · 1968
Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale
10.1016/0165-1781(92)90005-n · 1992
Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged >80years
10.3816/clc.2007.n.013 · 2007
Cancer and comorbidity in older patients: a descriptive profile
10.1016/s1047-2797(96)00063-4 · 1996
Step by step development of clinical care pathways for older cancer patients: necessary or desirable?
10.1016/j.ejca.2007.08.004 · 2007
Participation of patients 65years of age or older in cancer clinical trials
10.1200/jco.2003.08.010 · 2003
International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency
10.1016/j.ejca.2006.11.004 · 2007
Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach
10.1016/j.critrevonc.2005.04.008 · 2005
Comorbidity and survival of Danish breast cancer patients from 1995 to 2005
10.1038/sj.bjc.6603717 · 2007
Coprescription of tamoxifen and medications that inhibit CYP2D6
10.1200/jco.2009.23.8931 · doi-reference
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes
10.1200/jco.2002.09.064 · doi-reference
Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors
10.1200/jco.2006.08.9599 · doi-reference
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
10.1016/j.ejca.2006.06.017 · doi-reference
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
10.1093/annonc/mdl321 · doi-reference
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
10.1200/jco.2004.07.173 · doi-reference
Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients
10.1016/j.critrevonc.2008.12.006 · doi-reference
On behalf of the ESMO Guidelines Working Group: chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis
10.1093/annonc/mdp160 · doi-reference
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
10.1200/jco.2006.06.9591 · doi-reference
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
10.1093/annonc/mdj078 · doi-reference
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
10.1200/jco.1989.7.11.1693 · doi-reference
Updated clinical practice guidelines for the prevention and treatment of mucositis
10.1002/cncr.22484 · doi-reference
Dose adjustment and supportive care before and during treatment
10.1016/j.ctrv.2009.04.009 · doi-reference
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
10.1093/annonc/mdm011 · doi-reference
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events
10.1038/sj.bjc.6605255 · doi-reference
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
10.1038/sj.bjc.6605498 · doi-reference
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
10.1001/jama.299.8.914 · doi-reference
On behalf of the ESMO Guidelines Working Group: erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use
10.1093/annonc/mdp161 · doi-reference
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline
10.1200/jco.2006.06.4451 · doi-reference
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
10.1016/j.ejca.2006.05.002 · doi-reference
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
10.1002/cncr.22939 · doi-reference
Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer
10.1016/0959-8049(92)90459-f · doi-reference
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
10.1080/1042819031000119262 · doi-reference
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study
10.1200/jco.2005.09.102 · doi-reference
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
10.1200/jco.2006.06.9039 · doi-reference
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial
10.1093/jnci/94.3.173 · doi-reference
Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >=70years with advanced ovarian cancer—a study by the AGO OVAR Germany
10.1093/annonc/mdl401 · doi-reference
10.1016/j.ejca.2010.04.009
10.1016/j.ejca.2010.04.009 · doi-reference
Predictors of treatment failures during chemotherapy: a prospective study on 110 older cancer patients
10.1016/j.archger.2008.01.011 · doi-reference
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials
10.1200/jco.2007.12.8322 · doi-reference
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
10.1016/j.ygyno.2008.01.001 · doi-reference
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
10.1007/s10549-005-1410-8 · doi-reference
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature
10.1200/jco.2007.10.6583 · doi-reference
Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients
10.1007/s00432-007-0233-x · doi-reference
Multimorbidity and survival in older persons with colorectal cancer
10.1111/j.1532-5415.2006.00973.x · doi-reference
Comorbidity and ovarian cancer survival in Denmark, 1995–2005: a population-based cohort study
10.1111/j.1525-1438.2007.01036.x · doi-reference
Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study
10.1038/sj.pcan.4500868 · doi-reference
Impact of comorbidity on survival of Danish prostate cancer patients, 1995–2006: a population-based cohort study
10.1016/j.urology.2007.12.018 · doi-reference
Drug-induced illness as a cause for admission to a community hospital
10.1111/j.1532-5415.1989.tb05498.x · doi-reference
National surveillance of emergency department visits for outpatient adverse drug events
10.1001/jama.296.15.1858 · doi-reference